Author:
Robison Michelle,Bush Nancy Jo
Abstract
ABSTRACTProcesses for intravesical chemotherapy after transurethral resection of nonmuscle invasive bladder tumors may lack standardization. In 2019, at a large health care system in Los Angeles, California, five incident reports involving chemotherapeutic agent spills from urinary catheters after bladder tumor procedures necessitated a quality improvement project. The project lead determined that a cost‐effective alternative device for securing the chemotherapeutic agent in the bladder was needed at four surgical locations of the health care system. In addition, a review of the literature and an observational assessment revealed lack of adherence to standard and recommended processes for using personal protective equipment (PPE) when handling hazardous medications. After revising existing processes, acquiring a cost‐effective clamp and recommended chemotherapy PPE, instructing personnel on the clamping process and use of PPE, and implementing use of the clamp, there have been no spills associated with intravesical chemotherapy across the four surgical locations.
Reference21 articles.
1. Cancer Statistics, 2021
2. Key statistics for bladder cancer.American Cancer Society. Revised January 19 2024. Accessed January 25 2024.https://www.cancer.org/cancer/types/bladder‐cancer/about/key‐statistics
3. American Urological Association Society of Urologic Nurses and Associates.Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer. Amended September2020. Accessed January 18 2024.https://www.auanet.org/about‐us/policy‐and‐position‐statements/intravesical‐administration‐of‐therapeutic‐medication
4. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)